NY-ESO-1 antigen: A promising frontier in cancer immunotherapy

Alaa Alsalloum; Julia A. Shevchenko; Sergey Sennikov

doi:10.1002/ctm2.70020

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (9) : e70020 DOI: 10.1002/ctm2.70020

REVIEW

NY-ESO-1 antigen: A promising frontier in cancer immunotherapy

Author information +

History +

PDF

Abstract

	•Endogenous immune response: NY-ESO-1 exhibited high immunogenicity, activating endogenous dendritic cells, T cells and B cells.
	•NY-ESO-1-based cancer vaccines: NY-ESO-1 vaccines using protein/peptide, RNA/DNA, microbial vectors and artificial adjuvant vector cells have shown promise in enhancing immune responses against tumours.
	•NY-ESO-1-specific T-cell receptor-engineered cells: NY-ESO-1-targeted T cells, along with ongoing innovations in engineered natural killer cells and other cell therapies, have improved the efficacy of immunotherapy.

Keywords

cancer immunotherapy / cancer testis antigen / cancer vaccine / NY-ESO-1 / tumour microenvironment

Cite this article

Download citation ▾

Alaa Alsalloum,Julia A. Shevchenko,Sergey Sennikov. NY-ESO-1 antigen: A promising frontier in cancer immunotherapy. Clinical and Translational Medicine, 2024, 14(9): e70020 DOI:10.1002/ctm2.70020

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.